Logo image of DAWN

DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Fundamental Analysis

NASDAQ:DAWN - Nasdaq - US23954D1090 - Common Stock - Currency: USD

12.43  +0.2 (+1.64%)

After market: 12.43 0 (0%)

Fundamental Rating

3

Taking everything into account, DAWN scores 3 out of 10 in our fundamental rating. DAWN was compared to 571 industry peers in the Biotechnology industry. While DAWN has a great health rating, there are worries on its profitability. DAWN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DAWN has reported negative net income.
DAWN had a negative operating cash flow in the past year.
DAWN had negative earnings in each of the past 5 years.
In the past 5 years DAWN always reported negative operating cash flow.
DAWN Yearly Net Income VS EBIT VS OCF VS FCFDAWN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

DAWN has a Return On Assets of -14.03%. This is amongst the best in the industry. DAWN outperforms 85.08% of its industry peers.
The Return On Equity of DAWN (-15.18%) is better than 88.81% of its industry peers.
Industry RankSector Rank
ROA -14.03%
ROE -15.18%
ROIC N/A
ROA(3y)-49.95%
ROA(5y)-56.95%
ROE(3y)-52.68%
ROE(5y)-65.8%
ROIC(3y)N/A
ROIC(5y)N/A
DAWN Yearly ROA, ROE, ROICDAWN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DAWN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DAWN Yearly Profit, Operating, Gross MarginsDAWN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for DAWN has been increased compared to 1 year ago.
There is no outstanding debt for DAWN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DAWN Yearly Shares OutstandingDAWN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M
DAWN Yearly Total Debt VS Total AssetsDAWN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

DAWN has an Altman-Z score of 15.54. This indicates that DAWN is financially healthy and has little risk of bankruptcy at the moment.
DAWN has a better Altman-Z score (15.54) than 90.76% of its industry peers.
DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.54
ROIC/WACCN/A
WACCN/A
DAWN Yearly LT Debt VS Equity VS FCFDAWN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

DAWN has a Current Ratio of 14.62. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 14.62, DAWN belongs to the top of the industry, outperforming 88.63% of the companies in the same industry.
DAWN has a Quick Ratio of 14.55. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DAWN (14.55) is better than 88.45% of its industry peers.
Industry RankSector Rank
Current Ratio 14.62
Quick Ratio 14.55
DAWN Yearly Current Assets VS Current LiabilitesDAWN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.61% over the past year.
EPS 1Y (TTM)22.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DAWN will show a very strong growth in Earnings Per Share. The EPS will grow by 22.86% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.8%
EPS Next 2Y24.19%
EPS Next 3Y23.87%
EPS Next 5Y22.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DAWN Yearly Revenue VS EstimatesDAWN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
DAWN Yearly EPS VS EstimatesDAWN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DAWN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DAWN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DAWN Price Earnings VS Forward Price EarningsDAWN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DAWN Per share dataDAWN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as DAWN's earnings are expected to grow with 23.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.19%
EPS Next 3Y23.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DAWN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (2/21/2025, 8:12:02 PM)

After market: 12.43 0 (0%)

12.43

+0.2 (+1.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)02-25 2025-02-25/amc
Inst Owners94.33%
Inst Owner Change-98.62%
Ins Owners2.14%
Ins Owner Change-0.01%
Market Cap1.25B
Analysts82.5
Price Target36.15 (190.83%)
Short Float %20.83%
Short Ratio17.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.5%
Min EPS beat(2)11.53%
Max EPS beat(2)93.47%
EPS beat(4)2
Avg EPS beat(4)22.75%
Min EPS beat(4)-7.56%
Max EPS beat(4)93.47%
EPS beat(8)6
Avg EPS beat(8)13.82%
EPS beat(12)8
Avg EPS beat(12)5.97%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)334.88%
Min Revenue beat(2)-16.43%
Max Revenue beat(2)686.18%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.74%
PT rev (3m)-9.98%
EPS NQ rev (1m)20.69%
EPS NQ rev (3m)20.69%
EPS NY rev (1m)12.92%
EPS NY rev (3m)12.92%
Revenue NQ rev (1m)2.37%
Revenue NQ rev (3m)2.3%
Revenue NY rev (1m)1.67%
Revenue NY rev (3m)6.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.3
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 2.32
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.06
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS1.01
BVpS5.51
TBVpS5.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.03%
ROE -15.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.95%
ROA(5y)-56.95%
ROE(3y)-52.68%
ROE(5y)-65.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1871.49%
Cap/Sales 17.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.62
Quick Ratio 14.55
Altman-Z 15.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)224.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.48%
EPS Next Y68.8%
EPS Next 2Y24.19%
EPS Next 3Y23.87%
EPS Next 5Y22.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.87%
EBIT Next 3Y21.58%
EBIT Next 5YN/A
FCF growth 1Y-22.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.99%
OCF growth 3YN/A
OCF growth 5YN/A